CoChat

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Glioblastoma multiforme (GBM) is a fatal primary brain tumor harboring myriad genetic and epigenetic alterations. The recent multidimensional analysis of the GBM genome has provided a more complete view of the landscape of such alterations and their linked pathways. This effort has demonstrated that certain pathways are universally altered, but that the specific genetic events altered within each pathway can vary for each particular patient's tumor. With this atlas of genetic and epigenetic events, it now becomes feasible to assess how the patterns of mutations in a pathway influence response to drugs that are targeting such pathways. This issue is particularly important for GBM because, in contrast to other tumor types, molecularly targeted therapies have failed to alter overall survival substantially. Here, we combined functional genetic screens and comprehensive genomic analyses to identify CDK6 as a GBM oncogene that is required for proliferation and viability in a subset of GBM cell lines and tumors. Using an available small molecule targeting cyclin-dependent kinases (CDKs) 4 and 6, we sought to determine if the specific pattern of retinoblastoma pathway inactivation dictated the response to CDK4/6 inhibitor therapy. We showed that codeletion of CDKN2A and CDKN2C serves as a strong predictor of sensitivity to a selective inhibitor of CDK4/6. Thus, genome-informed drug sensitivity studies identify a subset of GBMs likely to respond to CDK4/6 inhibition. More generally, these observations demonstrate that the integration of genomic, functional and pharmacologic data can be exploited to inform the development of targeted therapy directed against specific cancer pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1001613107

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 228

Metadata

Authors
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., Shapiro, G. I., Hahn, W. C., & Chin, L.
Affiliations
  • Harvard University (US)
  • Broad Institute (US)
  • The Belfer Institute for Applied Cancer Science and
Venue
Proceedings of the National Academy of Sciences
Published
2010-06-07
Volume
107
Issue
25
Pages
11501-11506
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2036013203
Cited by
223
References
22
Citations by year
2026: 4 · 2025: 3 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 11 · 2020: 16 · 2019: 24 · 2018: 12 · 2017: 24 · 2016: 16 · 2015: 11 · 2014: 15 · 2013: 14 · 2012: 19
FWCI
6.71
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
National Institute of Neurological Disorders and Stroke (K08NS062907)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
glioblastoma, CDK4/6 inhibitors, retinoblastoma pathway, CDKN2A, CDKN2C, drug response prediction, targeted therapy, cyclin-dependent kinases, tumor genomic alterations
MeSH terms
Animals, Dose-Response Relationship, Drug, Enzyme Inhibitors, Glioblastoma, Humans, Neoplasm Transplantation, Piperazines, Pyridines, Gene Expression Regulation, Neoplastic, Retinoblastoma Protein, Central Nervous System Neoplasms, Inhibitory Concentration 50, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p18, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. https://app.cochat.ai/papers/10.1073/pnas.1001613107
The paper
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., Shapiro, G. I., Hahn, W. C., & Chin, L. (2010). Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1001613107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.